Vivimed Labs Limited · NSE:VIVIMEDLAB
Vivimed Labs — Q2 FY2017 Earnings Presentation
14 slides from Vivimed Labs's earnings presentation, Nov 12, 2016
Slide 1: Exchange filing cover letter
Date: 16.11.2016 To BSE Limited P.J.Towers, Dalal Street, Mumbai — 400001 BSE - Code : 532660 Dear Sir / Madam, Vivimed National Stock Exchange of India Ltd. Exchange Plaza,Plot no. C/1, G Block, Bandra-Kurla Complex, Bandra (E) Mumbai - 400 051 NSE- Symbol: VIVIMEDLAB Sub:Earnings Presentation on Q
Slide 2: Second Quarter FY2017 Earnings Presentation
Second Quarter FY2017 Earnings Presentation November 12, 2016 Transitioning into the Next Phase of Growth
Slide 3: Disclaimer
Disclaimer This presentation contains statements that contain “forward looking statements” including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to Vivimed Labs’ future business developments and economic performance. Whil
Slide 4: Transitioning into the Next Phase of Growth
Transitioning into the Next Phase of Growth Leveraging chemistry skills and quality compliant manufacturing platform to scale up custom manufacturing and generic product revenue lines within the API vertical Harvesting blue chip customer base more effectively by introduction of new and competitive p
Slide 5: Performance Highlights
Performance Highlights Q2 FY2017 vs. Q2 FY2016 H1 FY2017 vs. H1 FY2016 Net Sales Net Profit Net Sales Net Profit Rs. 2,993 mn Rs. 269 mn Rs. 6,679 mn Rs. 547 mn (12.4)% +12.5% (1.0)% +13.9% 27.2% 24.2% Net Profit Net Profit Margin: Margin: 72.8% 9.0% 8.2% 75.8% Healthcare Specialty Chemicals +198 bp
Slide 6: Management Perspectives
Management Perspectives Commenting on the performance, Mr. Santosh Varalwar, Managing Director of Vivimed Labs said: “The performance during the first half of the fiscal year was in-line with our expectations. Pharmaceuticals vertical accounted for 76% of the total revenue during H1 FY2017 and the b
Slide 7: Financial Performance
Financial Performance Consolidated financial summary Q2 y-o-y Q1 q-o-q Half Year y-o-y (Rs. million) FY2017 FY2016 Growth (%) FY2017 Growth (%) FY2017 FY2016 Growth (%) Net Sales 2,993 3,415 (12.4)% 3,686 (18.8)% 6,679 6,745 (1.0)% EBITDA 612 632 (3.1)% 668 (8.4)% 1,281 1,304 (1.8)% Margin (%) 20.5%
Slide 8: Performance Discussion
Performance Discussion H1 FY2017 vs. H1 FY2016 Revenues declined by 1.0% y-o-y to Rs. 6,679 million o Pharmaceuticals segment recorded a growth of 5.4% y-o-y to reach Rs. 5,041 million. This growth was primarily driven by improved performance of the API segment, in particular, the custom manufactu
Slide 9: Financial Performance
Financial Performance Net Sales EBITDA and Margins 3,686 3,415 3,500 3,319 668 632 613 612 Rs. Million 2,993 Rs. Million 512 20.5% 18.5% 18.5% 18.1% 14.6% Q2 FY16 Q3 FY16 Q4 FY16 Q1 FY17 Q2 FY17 Q2 FY16 Q3 FY16 Q4 FY16 Q1 FY17 Q2 FY17 EBITDA Margin (%) Net Profit and Margins 279 269 239 230 7.6% 9.0
Slide 10: Consolidated Quarterly P&L Statement
Consolidated Quarterly P&L Statement Profit & Loss Statement (Rs. million) Q2 FY16 Q3 FY16 Q4 FY16 Q1 FY17 Q2 FY17 Revenues Net Sales / Income from Operations (Net of Excise Duty) 3,370 3,299 3,472 3,668 2,984 Other Operating Income 45 20 29 18 9 Total Revenues 3,415 3,319 3,500 3,686 2,993 Total ex
Slide 11: Consolidated Segment Performance
Consolidated Segment Performance Q2 y-o-y Q1 q-o-q Half Year y-o-y (Rs. million) FY2017 FY2016 Growth (%) FY2017 Growth (%) FY2017 FY2016 Growth (%) Segment Revenue 2,984 3,370 (11.5)% 3,668 (18.7)% 6,652 6,686 (0.5)% Specialty Chemicals 811 943 (14.0)% 800 1.4% 1,611 1,901 (15.3)% Pharmaceuticals 2
Slide 12: Key Ratios
Key Ratios FY2011 FY2012 FY2013 FY2014 FY2015 FY2016 H1 FY2017 Net Worth (Rs. million) 1,967 4,748 5,091 5,604 5,592 5,852 6,151 Net Debt (Rs. million) 2,959 5,279 6,414 8,591 9,852 8,618 8,074 Including current maturities of LT Debt Fixed Assets (Rs. million) 2,643 5,953 7,090 8,079 8,135 8,142 8,0
Slide 13: Glossary
Glossary ANDA: Abbreviated New Drug Application API: Active Pharmaceutical Ingredients CEP: Certificates of Suitability to the monographs of European Pharmacopoeia CMO: Contract Manufacturing Organization DMF: Drug Master File FDF: Finished Dosage Formulation GMP: Good Manufacturing Pr
Slide 14: Vivimed Labs Limited
Vivimed Labs Limited (CIN: L02411KA1988PLC009465) Veernag Towers, Habsiguda Hyderabad 500 007 www.vivimedlabs.com Phone: +91 40 2717 6005 / 06 Fax: +91 40 2715 0599 Raja Prasad B. +91 40 2717 6005 Vivimed Labs Limited Rajaprasad.B@vivimedlabs.com Saket Somani / Bijay Sharma +91 22 6169 5988 Churchga